When additional therapy is required, NICE recommends considering a GLP-1 receptor agonist (such as Rybelsus) if the patient has a BMI of 35 kg/m or higher (or 32.5 kg/m or higher for people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity, or if BMI is lower but insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities
What to Avoid While Using the Medication: Minimize alcohol consumption, and be cautious about mixing with certain diabetes medications without talking to your healthcare provider
The counterargument is that SGLT-2i probably has a stronger case in relation to cardiovascular protection, particularly reduction in heart failure hospitalization, but these agents can be problematic in those with urinary tract pathologies or significant renal impairment
Nery FG, Tallman MJ, Cecil KM, Blom TJ, Patino LR, Adler CM, et al
At TrimRx, we recognize that weight loss is not just about the medication itself, but about finding the specific rhythm that works for your bodys unique metabolic needs
One is potential side effects: They basically have the same side effects, Dr